Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 180

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 180
---
 lease liabilities, non-current
         
        838

        12,434

        Total operating lease liabilities
        $
        1,190

        $
        13,286

        Weighted-average remaining lease term (years)
         
        3.47

        8.42

        Weighted-average discount rate
         
        13.70
        %

        5.75
        %

       Other information related to leases for the years ended December 31, 2024, 2023, and 2022, respectively, were as follows: 

        Year Ended December 31,

        (in thousands)
        2024

        2023

        2022

        Net cash paid (received) for amounts included in the measurement of lease liabilities
        $
        1,202

        $
        1,447

        $
        (1,089
        )

        Leased assets (derecognized) obtained in exchange for new or modified operating lease liabilities
         
        (11,524
        )

        —

        987

       Future minimum lease payments, net of reimbursements, remaining as of December 31, 2024, under operating leases by fiscal year were as follows: 

        Fiscal year

        (in thousands)

        2025

        $
        480

        2026

        483

        2027

        205

        2028

        152

        Thereafter

        155

        Total lease payments

        $
        1,475

        Less: Present Value Adjustment

        (285
        )

        Present value of lease payments

        $
        1,190

       Rent expense recorded for the years ended December 31, 2024, 2023, and 2022, were $1,194, $1,913, and $2,215 respectively. ContingenciesFrom time to time, the Company may have certain contingent liabilities that arise in the ordinary course of its business activities. The Company accrues a liability for such matters when future expenditures are probable and such expenditures can be reasonably estimated. 

 116

7.  Stockholders’ EquityThe Company is authorized to issue up to 1,000,000,000 shares of common stock with a par value of $0.00001 per share, and 5,000,000 shares of preferred stock with a